Cassini announced that it has closed a Series A financing round with venture capital fund Innovation Industries. The injection of capital will accelerate the development and successful commercialization of Cassini, a diagnostic platform for premium refractive cataract surgery procedures.
Terms of the financing were not disclosed.
Since its launch in 2013, Cassini has been at the forefront of improving cataract surgery outcomes by providing diagnostic analysis of the total cornea, including the posterior surface. At the 2017 Congress of the European Society of Cataract and Refractive Surgeons in Lisbon, Portugal, 12 studies were presented demonstrating outstanding diagnostic accuracy and clinical outcomes based on Cassini’s performance. Covering a wide range of research interests, the studies focused on measurement of the posterior cornea, precision of femtosecond laser assisted arcuate incisions for correction of astigmatism, and comparative studies of Cassini and other diagnostic technologies.
“Innovation Industries shares our long-term vision of continuous innovation with the goal of delivering the best possible refractive outcomes to patients, while at the same time improving operational efficiencies and providing to surgeons and industry partners an indispensable technology platform for seamless integration of the clinic and surgical suite," Jeroen Cammeraat, CEO, said in a news release.
“We are very excited about our investment in Cassini”, says Chris Sonnenberg, General Partner at Innovation Industries. “Cassini has built an impressive global customer base and has started to generate very compelling clinical data. We strongly support the vision of the leadership team to accelerate R&D and clinical study efforts to bring Cassini to the next performance level and expand strategic partnerships to other key players in the industry”.